Do you want to read an article? Please log in or register.
Real-life efficacy of guselkumab in patients with early psoriatic arthritis
Further Publications Rheumatology
Related content
Further Publications Rheumatology
Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Arthritis Rheumatol
McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, van der Heijde D, Mease PJ
doi: 10.1002/art.42010
Psoriatic Arthritis
Comparing the patient reported physical function outcome measures in a real-life international cohort of patients with psoriatic arthritis
Arthritis Care Res (Hoboken).
Leung YY, Orbai AM, de Wit M, Balanescu A, Dernis E, Soubrier M, Eder L, Smolen JS, Coates LC, Gossec L, ReFlap Study Group.
doi: 10.1002/acr.24139.
Psoriatic Arthritis
Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: Results through week 24 of the GO-VIBRANT study
Arthritis Rheumatol.
Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC
doi: 10.1002/art.40226.
Psoriatic Arthritis
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Rheumatol Ther.
Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, FitzGerald O, Fleishaker D, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Romero AB, Kanik KS
doi: 10.1007/s40744-020-00209-4.
COMMENTED
Psoriatic Arthritis
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1016/S0140-6736(20)30265-8.
Psoriatic Arthritis
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
Arthritis Res Ther.
Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group
doi: 10.1186/s13075-018-1773-y.
COMMENTED
Psoriatic Arthritis
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Ann Rheum Dis.
Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS, SPIRIT H2H study group.
doi: 10.1136/annrheumdis-2019-215386.
Psoriatic Arthritis
Efficacy and Safety of Intravenous Golimumab through 1 Year in Patients with Active Psoriatic Arthritis
Arthritis Care Res (Hoboken).
Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC
doi: 10.1002/acr.23905.
Psoriatic Arthritis
Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
Arthritis Res Ther.
Strand V, Alemao E, Lehman T, Johnsen A, Banerjee S, Ahmad HA, Mease PJ
doi: 10.1186/s13075-018-1769-7.